Skip to content
thispeptide

Bayan Health

Bayan Health sells sermorelin, NAD+, glutathione, PT-141 and GHK-Cu cream beside compounded GLP-1s, each at one monthly price with the doctor's fee folded in. The catch is the lock-in: most plans run two or three months and cannot be canceled early.

Review by Molly Ward, goal-guide writer · Updated October 2026

The short version

Bayan is unusually open about its fees and keeps a single price at every GLP-1 dose. It is much less open about doses: no peptide page prints one. Its refund policy is strict, so treat the first two or three months as a firm purchase.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Lowest listed: GHK-Cu topical, from $69/mo

All 50 states

Visit Bayan Health →

Bayan Health is a cash-pay telehealth for weight loss, longevity, hormones, skin and sexual health, founded by a nurse anesthetist. Its shop runs to about sixty products: compounded GLP-1s, peptides from sermorelin to PT-141, hormone creams, erectile dysfunction pills and lab panels.

What Bayan Health prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)From $129/mo
    • Oral (compounded)Price not published
  • TirzepatideFDA-approved
    • Injection (compounded)From $149/mo
    • Oral (compounded)Price not published
  • OrforglipronFDA-approved

    Listed by the seller; no price we hold.

    Compounded semaglutide and tirzepatide are once-a-week injections with vitamin B6, at a flat price whatever the dose. Lower-priced microdose versions are sold beside them, and so is a compounded orforglipron tablet taken daily. No milligram strength is printed for any of them.

    Sexual health

    PT-141 is an injection sold as a two-month plan. The page explains that it works on the brain rather than on blood flow. It prints no dose. It does say the brand version, Vyleesi, is approved for a specific use in premenopausal women.

    Longevity

    • GlutathioneLegal to compound
      • Injection (compounded)From $89/mo
    • NAD+Legal to compound
      • Injection (compounded)From $99/mo$120 a calendar month, our arithmetic
      • Nasal spray (compounded)From $119/mo

    NAD+ comes as an injection or a daily nasal spray. The injection page prints a dose, 100 mg twice a week, and ships two 10 mL vials at 100 mg per mL as a ten-week supply. The spray ships three months at a time with no dose printed. Glutathione is a two-month plan with a 10 mL vial at 200 mg per mL, again with no dose. GHK-Cu comes as a face cream, an "advanced" face cream and a hair foam, all on three-month plans.

    Recovery

    • GHK-CuLegal to compound
      • Topical (compounded)From $69/mo
    • SermorelinLegal to compound
      • Injection (compounded)From $99/mo

    Sermorelin is the product for recovery too, on the same three-month plan. Glutathione is pitched for recovery as well, as a 200 mg per mL vial. Neither page cites a study.

    Sleep

    • SermorelinLegal to compound
      • Injection (compounded)From $99/mo

    Sermorelin is an injection sold as a three-month plan. The page prints the vial, 0.9 mg per mL in a 10 mL vial, but no dose or schedule; the physician sets both.

    Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

    Who prescribes

    A licensed clinician

    Prescriptions come through MD Integrations, the nationwide physician network Bayan names as its partner. A page profiles that network's founder, but the doctor who reviews your case is not named.

    You choose a product, pay at checkout and then fill in a short medical questionnaire. The FAQ says you meet a clinician by video, audio or secure message, and the weight-loss page describes a video visit. Your card is charged only if a physician approves you. Provider messaging and follow-up visits are included in the monthly price.

    Are labs required?

    Optional, sold separately

    Labs are not required for the peptide plans. Bayan sells blood panels as separate purchases, from a $149 baseline panel to a $499 full-body panel, and the FAQ says labs are ordered when needed.

    Ready to start with Bayan Health?

    Lowest listed price: GHK-Cu topical, from $69/mo. Confirm it on the seller’s own site.

    Visit Bayan Health →

    What it claims, and what it cites

    The GLP-1 pages promise weight loss of up to 15% for semaglutide and 20 to 26% for tirzepatide. Each now names its trial, and the semaglutide page notes that trial studied the same active ingredient. The results page leads with the founder's own 56-pound loss. The peptide pages describe benefits in general terms and cite nothing.

    On Bayan Health’s siteSource it gives
    On Bayan Health’s site“weight loss of up to 15% of total body weight based on clinical research”Source it givesWilding et al., New England Journal of Medicine, 2021
    On Bayan Health’s site“weight reductions up to 20-26% based on the SURMOUNT-3 clinical trial”Source it givesWadden et al., Nature Medicine, 2023 (SURMOUNT-3)
    On Bayan Health’s site“56 lbs lost by our founder”Source it givesNone given
    On Bayan Health’s site“helps stimulate your body's natural growth hormone production”Source it givesNone given

    Sold by Bayan Health, not listed here

    BPC-157
    On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    Epitalon
    On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
    KPV
    On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    MOTS-c
    On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    Oxytocin
    We have not yet read its FDA status, so we list no seller for it.
    Selank
    On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
    Semax
    On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
    SS-31
    On no FDA compounding list. Neither SS-31 nor elamipretide, the name it is studied under, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).
    TB-500
    On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    Tesamorelin
    Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
    Thymosin alpha-1
    "Thymosin alpha-1" is in 503B Category 3, bulk drug substances nominated without adequate support (list updated March 21, 2025). It is named on no 503A list, so no listed compounding route exists for it.
    Tesamorelin
    Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
    MOTS-c
    On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    BPC-157
    On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
    Orforglipron tablets
    Foundayo (orforglipron) tablets, NDA 220934, approved April 1, 2026 for chronic weight management.
    GHK-Cu injection
    Injected GHK-Cu may not be compounded, so only the creams and foam are covered here.
    TB-500, CJC-1295/ipamorelin, AOD-9604, KPV, SS-31, epithalon, thymosin alpha-1, selank, semax, dihexa, melanotan-2 and the Glow and Wolverine blends
    Research peptides and blends this site does not cover.
    Retatrutide and cagrilintide
    Investigational weight-loss drugs this site does not cover.
    Estradiol, progesterone, enclomiphene and testosterone
    Hormone treatments, which this site does not cover.
    Sildenafil, tadalafil, oxytocin spray and skin creams
    Medicines that are not peptides.

    How it bills

    Sermorelin is $99 a month, billed over a three-month protocol that ships at once. NAD+ by injection is $99 every 25 days and the spray $119 a month, both running until you cancel. Glutathione is $89 a month and PT-141 is $199, each billed over two months. Shipping is free and the consultation fee is included. The terms ask for 15 days' notice before the next protocol cycle, and say consultation fees are generally not refunded once clinical review has begun.

    Availability: All 50 states

    For and against

    • For: Consult and shipping in one price
    • For: One GLP-1 price at every dose
    • For: Card charged only after approval
    • For: Free shipping on every plan
    • Against: Most protocols bill over two or three months
    • Against: No dose printed for most peptides
    • Against: Little refunded once review begins
    • Against: Prescribing doctors not named

    The evidence behind what it sells

    Right for

    Readers who plan to stay on sermorelin, NAD+ or glutathione for a few months and want the doctor's fee folded into one monthly price.

    Look elsewhere if

    Anyone who wants sermorelin, glutathione or PT-141 for a single month, a printed dose before paying, or the option of a refund.

    Other sellers for weight

    Bayan Health

    Frequently asked questions

    Can I cancel Bayan sermorelin after the first month?
    Sermorelin is sold as a three-month protocol billed at $99 a month, and the whole supply ships at once. The terms ask for notice at least 15 days before the next protocol cycle, or a new one can start.
    Is a doctor visit included in Bayan's price?
    Yes. Every product page says the physician consultation fee is included in the monthly price, and shipping is free.
    Am I charged if Bayan's physician does not approve me?
    Checkout says the card is only authorized and is charged after approval. The terms add that consultation fees are generally not refunded once clinical review has begun.

    See what Bayan Health prescribes today

    Bayan Health sets its own prices, plans and the states it serves. Check them before you start.

    Visit Bayan Health →
    Written by Molly Ward from Bayan Health’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.